Full Text Journal Articles by
Author Lukas Bubendorf

Advertisement

Find full text journal articles






Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.

Simon Haefliger, Deepali Jain, Thomas Menter, Tatjana Vlajnic, Spasenija Savic Prince, Helmut Hopfer, Michael J Mihatsch, Lukas Bubendorf,

INTRODUCTION:In effusion cytology, mesothelial cells can occasionally present with striking intracytoplasmic accumulation of rod- and crystal-like cytoplasmic lamellar inclusions (LIs). Their nature and function are poorly understood, and their diagnostic relevance is unknown. OBJECTIVE:The aim of this study was to explore the nature of LIs in mesothelial cells and determine ... Read more >>

Acta Cytol. (Acta cytologica)
[2020, :1-5]

Cited: 0 times

View full text PDF listing >>



Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.

Oliver Gautschi, Lukas Bubendorf, Serge Leyvraz, Roopika Menon, Joachim Diebold,

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, 15(7):e108-e110]

Cited: 0 times

View full text PDF listing >>



Advertisement

A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee.

Andre L Moreira, Paolo Ss Ocampo, Yuhe Xia, Hua Zhong, Prudence A Russell, Yuko Minami, Wendy A Cooper, Akihiko Yoshida, Lukas Bubendorf, Mauro Papotti, Giuseppe Pelosi, Fernando Lopez-Rios, Keiko Kunitoki, Dana Ferrari-Light, Lynette M Sholl, Mary Beth Beasley, Alain Borczuk, Johan Botling, Elisabeth Brambilla, Gang Chen, Teh-Ying Chou, Jin-Haeng Chung, Sanja Dacic, Deepali Jain, Fred R Hirsch, David Hwang, Sylvie Lantuejoul, Dongmei Lin, John W Longshore, Noriko Motoi, Masayuki Noguchi, Claudia Poleri, Natasha Rekhtman, Ming-Sound Tsao, Erik Thunnissen, William D Travis, Yasushi Yatabe, Anja C Roden, Jillian B Daigneault, Ignacio I Wistuba, Keith M Kerr, Harvey Pass, Andrew G Nicholson, Mari Mino-Kenudson,

INTRODUCTION:A grading system for pulmonary adenocarcinoma has not been established. The IASLC pathology panel evaluated a set of histological criteria associated with prognosis aimed at establishing a grading system for invasive pulmonary adenocarcinoma. DESIGN:A multi-institutional study involving multiple cohorts of invasive pulmonary adenocarcinomas was conducted. A cohort of 284 stage ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee.

Lynette M Sholl, Fred R Hirsch, David Hwang, Johan Botling, Fernando Lopez-Rios, Lukas Bubendorf, Mari Mino-Kenudson, Anja C Roden, Mary Beth Beasley, Alain Borczuk, Elisabeth Brambilla, Gang Chen, Teh-Ying Chou, Jin-Haeng Chung, Wendy A Cooper, Sanja Dacic, Sylvie Lantuejoul, Deepali Jain, Dongmei Lin, Yuko Minami, Andre Moreira, Andrew G Nicholson, Masayuki Noguchi, Mauro Papotti, Giuseppe Pelosi, Claudia Poleri, Natasha Rekhtman, Ming-Sound Tsao, Erik Thunnissen, William Travis, Yasushi Yatabe, Akihiko Yoshida, Jillian B Daigneault, Ahmet Zehir, Solange Peters, Ignacio I Wistuba, Keith M Kerr, John W Longshore,

Immune checkpoint inhibitor therapies have revolutionized the management of patients with non-small cell lung carcinoma (NSCLC) and have led to unprecedented improvements in response rates and survival in a subset of a patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, :]

Cited: 0 times

View full text PDF listing >>



The Genomic Landscape of Prostate Cancer Brain Metastases

Antonio Rodriguez, John Gallon, Dilara Akhoundova, Sina Maletti, Alison Ferguson, Joanna Cyrta, Ursula Amstutz, Andrea Garofoli, Viola Paradiso, Scott Tomlins, Ekkehard Hewer, Vera Genitsch, Achim Fleischmann, Elisabeth Rushing, Rainer Grobholz, Ingeborg Fischer, Wolfram Jochum, Gieri Cathomas, Lukas Bubendorf, Holger Moch, Charlotte K.Y. Ng, Silke Gillessen Sommer, Salvatore Piscuoglio, Mark Rubin,

Abstract Lethal prostate cancer commonly metastasizes to bone, lymph nodes, and visceral organs but with more effective therapies, there is an increased frequency of metastases to the brain. Little is known about the genomic drivers of prostate cancer brain metastases (PCBM). To address this, we conducted a comprehensive multi-regional, genomic, ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.

Cleo Keppens, Elisabeth M C Dequeker, Etienne Rouleau, Nils 't Hart, Lukas Bubendorf, Kelly Dufraing, Céline Garrec, Paul Guéguen, Aude Lamy, Antonio Marchetti, Patrick Pauwels, Ales Ryska, Véronique Tack, Luigi Tornillo, Kaat Van Casteren, Jan H von der Thüsen, Karen Zwaenepoel, Birgit Lissenberg-Witte, Erik Thunnissen, Ed Schuuring,

BACKGROUND:Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired EGFR TKI resistance in non-small cell lung cancer. The aim of this study was to evaluate the correct detection of this variant in 12 tumor tissue specimens tested by ... Read more >>

BMC Cancer (BMC cancer)
[2020, 20(1):366]

Cited: 0 times

View full text PDF listing >>



CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.

Abdullah Alajati, Mariantonietta D'Ambrosio, Martina Troiani, Simone Mosole, Laura Pellegrini, Jingjing Chen, Ajinkya Revandkar, Marco Bolis, Jean-Philippe Theurillat, Ilaria Guccini, Marco Losa, Arianna Calcinotto, Gaston De Bernardis, Emiliano Pasquini, Rocco D'Antuono, Adam Sharp, Ines Figueiredo, Daniel Nava Rodrigues, Jonathan Welti, Veronica Gil, Wei Yuan, Tatjana Vlajnic, Lukas Bubendorf, Giovanna Chiorino, Letizia Gnetti, Verónica Torrano, Arkaitz Carracedo, Laura Camplese, Susumu Hirabayashi, Elena Canato, Gianfranco Pasut, Monica Montopoli, Jan Hendrik Rüschoff, Peter Wild, Holger Moch, Johann De Bono, Andrea Alimonti,

The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic alterations leading to CRPC may reveal potential vulnerabilities for cancer therapy. Here we find that CUB domain-containing protein 1 (CDCP1), a transmembrane protein that ... Read more >>

J. Clin. Invest. (The Journal of clinical investigation)
[2020, 130(5):2435-2450]

Cited: 0 times

View full text PDF listing >>



Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.

Tamara L Lotan, Scott A Tomlins, Tarek A Bismar, Theodorus H Van der Kwast, David Grignon, Lars Egevad, Glen Kristiansen, Colin C Pritchard, Mark A Rubin, Lukas Bubendorf,

The combined clinical and molecular heterogeneity of prostate cancer necessitates the use of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment selection. The pathologist plays a critical role in guiding molecular biomarker testing in prostate cancer and requires a thorough knowledge of the current testing options. In ... Read more >>

Am. J. Surg. Pathol. (The American journal of surgical pathology)
[2020, 44(7):e15-e29]

Cited: 0 times

View full text PDF listing >>



IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.

William D Travis, Sanja Dacic, Ignacio Wistuba, Lynette Sholl, Prasad Adusumilli, Lukas Bubendorf, Paul Bunn, Tina Cascone, Jamie Chaft, Gang Chen, Teh-Ying Chou, Wendy Cooper, Jeremy J Erasmus, Carlos Gil Ferreira, Jin-Mo Goo, John Heymach, Fred R Hirsch, Hidehito Horinouchi, Keith Kerr, Mark Kris, Deepali Jain, Young T Kim, Fernando Lopez-Rios, Shun Lu, Tetsuya Mitsudomi, Andre Moreira, Noriko Motoi, Andrew G Nicholson, Ricardo Oliveira, Mauro Papotti, Ugo Pastorino, Luis Paz-Ares, Giuseppe Pelosi, Claudia Poleri, Mariano Provencio, Anja C Roden, Giorgio Scagliotti, Stephen G Swisher, Erik Thunnissen, Ming S Tsao, Johan Vansteenkiste, Walter Weder, Yasushi Yatabe,

Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions on the degree of pathologic response, including major pathologic response or complete pathologic response. ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, 15(5):709-740]

Cited: 0 times

View full text PDF listing >>



PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Sylvie Lantuejoul, Ming Sound-Tsao, Wendy A Cooper, Nicolas Girard, Fred R Hirsch, Anja C Roden, Fernando Lopez-Rios, Deepali Jain, Teh-Ying Chou, Noriko Motoi, Keith M Kerr, Yasushi Yatabe, Elisabeth Brambilla, John Longshore, Mauro Papotti, Lynette M Sholl, Erik Thunnissen, Natasha Rekhtman, Alain Borczuk, Lukas Bubendorf, Yuko Minami, Mary Beth Beasley, Johan Botling, Gang Chen, Jin-Haeng Chung, Sanja Dacic, David Hwang, Dongmei Lin, Andre Moreira, Andrew G Nicholson, Masayuki Noguchi, Giuseppe Pelosi, Claudia Poleri, William Travis, Akihiko Yoshida, Jillian B Daigneault, Ignacio I Wistuba, Mari Mino-Kenudson,

The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, 15(4):499-519]

Cited: 0 times

View full text PDF listing >>



Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.

Erik Thunnissen, Keith M Kerr, Urania Dafni, Lukas Bubendorf, Stephen P Finn, Alex Soltermann, Wojciech Biernat, Richard Cheney, Erik Verbeken, Arne Warth, Antonio Marchetti, Ernst-Jan M Speel, Saraswati Pokharel, Anne Marie Quinn, Kim Monkhorst, Atilio Navarro, Line Bille Madsen, Zoi Tsourti, Thomas Geiger, Roswitha Kammler, Solange Peters, Rolf A Stahel, ,

PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer. Different scoring methods have been used to assess its status, resulting in a wide range of positivity rates. We use the European Thoracic Oncology Platform Lungscape non-small cell lung carcinoma cohort to explore this issue. ... Read more >>

Mod. Pathol. (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2020, 33(5):792-801]

Cited: 0 times

View full text PDF listing >>



Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Ilaria Alborelli, Katharina Leonards, Sacha I Rothschild, Laura P Leuenberger, Spasenija Savic Prince, Kirsten D Mertz, Severin Poechtrager, Martin Buess, Alfred Zippelius, Heinz Läubli, Jasmin Haegele, Markus Tolnay, Lukas Bubendorf, Luca Quagliata, Philip Jermann,

In non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive biomarker for patients treated with ICIs. Here, we evaluated the predictive power of TMB measured by the Oncomine™ Tumor Mutational Load targeted sequencing assay in 76 ... Read more >>

J. Pathol. (The Journal of pathology)
[2020, 250(1):19-29]

Cited: 0 times

View full text PDF listing >>



The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.

Esmée I M L Liem, Jorg R Oddens, Robin W M Vernooij, Roger Li, Ashish Kamat, Colin P Dinney, Lourdes Mengual, Antonio Alcaraz, Laura Izquierdo, Spasenija Savic, George N Thalmann, Lukas Bubendorf, Richard J Sylvester, Theo M de Reijke,

PURPOSE:The objective of this study was to assess the value of fluorescence in situ hybridization to predict early recurrence in patients with nonmuscle invasive bladder cancer at intermediate and high risk treated with bacillus Calmette-Guérin. MATERIALS AND METHODS:We performed a systematic review using MEDLINE®, Embase® and the Cochrane Library. Individual ... Read more >>

J. Urol. (The Journal of urology)
[2020, 203(2):283-291]

Cited: 0 times

View full text PDF listing >>



Extensive Emperipolesis of Neoplastic Lymphocytes by Mesothelial Cells in Pleural Effusion Cytology in a Case of a Mediastinal T-Cell Lymphoblastic Lymphoma: A Rare but Diagnostically Useful Phenomenon.

Simon Haefliger, Julien Rebetez, Paul J Buser, Stefan Dirnhofer, Lukas Bubendorf,

Emperipolesis is a biological process defined by the presence of an intact cell within the cytoplasm of another cell. In pleural fluid cytology, the phenomenon is very rare but has already been described in B-cell lymphoma. Here, we report the first case of a T-cell lymphoma diagnosed on a pleural ... Read more >>

Acta Cytol. (Acta cytologica)
[2020, 64(3):274-278]

Cited: 0 times

View full text PDF listing >>



Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Richard S P Huang, Derek Smith, Catherine H Le, Wen-Wei Liu, Ellen Ordinario, Chitra Manohar, Michael Lee, Jaya Rajamani, Huan Truong, Jing Li, Cindy Choi, Jingchuan Li, Amrita Pati, Lukas Bubendorf, Reinhard Buettner, Keith M Kerr, Fernando Lopez-Rios, Antonio Marchetti, Ivonne Marondel, Andrew G Nicholson, Ayşim Büge Öz, Patrick Pauwels, Frederique Penault-Llorca, Giulio Rossi, Erik Thunnissen, Amy Hanlon Newell, Greg Pate, Ina Menzl,

CONTEXT.—:The ability to determine ROS1 status has become mandatory for patients with lung adenocarcinoma, as many global authorities have approved crizotinib for patients with ROS1-positive lung adenocarcinoma. OBJECTIVE.—:To present analytical correlation of the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody (ROS1 [SP384] antibody) with ROS1 fluorescence in situ hybridization (FISH). ... Read more >>

Arch. Pathol. Lab. Med. (Archives of pathology & laboratory medicine)
[2020, 144(6):735-741]

Cited: 0 times

View full text PDF listing >>



The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH.

Tatjana Vlajnic, André Gut, Spasenija Savic, Lukas Bubendorf,

AIMS:The Paris System (TPS) was introduced in the diagnostic routine with the goal to simplify and standardise diagnostic reporting of urinary cytology. The diagnostic categories of TPS are based on defined cytological criteria, with a focus on high-grade urothelial carcinoma (HGUC). While the categories 'negative for HGUC (NHGUC)' and 'HGUC' ... Read more >>

J. Clin. Pathol. (Journal of clinical pathology)
[2020, 73(2):90-95]

Cited: 0 times

View full text PDF listing >>



Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.

Sarah G Dugas, David C Müller, Clémentine Le Magnen, Joel Federer-Gsponer, Hans-Helge Seifert, Christian Ruiz, Spasenija Savic Prince, Tatjana Vlajnic, Tobias Zellweger, Kirsten D Mertz, Jack V W Bacon, Alexander W Wyatt, Cyrill A Rentsch, Lukas Bubendorf,

BACKGROUND:Mutations of AT-rich interactive domain 1 (ARID1A) have been associated with a worse outcome after intravesical treatment with bacille Calmette-Guérin in patients with non-muscle-invasive bladder cancer (NMIBC). Loss of ARID1A protein expression in urine cytology may serve as an indication of an ARID1A mutation. Therefore, the authors examined the expression ... Read more >>

Cancer Cytopathol (Cancer cytopathology)
[2019, 127(9):578-585]

Cited: 0 times

View full text PDF listing >>



Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).

Ivana Bratic Hench, Richard Cathomas, Luigi Costa, Natalie Fischer, Silke Gillessen, Jürgen Hench, Thomas Hermanns, Eloïse Kremer, Walter Mingrone, Ricardo Pereira Mestre, Heike Püschel, Christian Rothermundt, Christian Ruiz, Markus Tolnay, Philippe Von Burg, Lukas Bubendorf, Tatjana Vlajnic, Swiss Group For Clinical Cancer Research Sakk,

Despite several treatment options and an initial high response rate to androgen deprivation therapy, the majority of prostate cancers will eventually become castration-resistant in the metastatic stage (mCRPC). Androgen receptor splice variant 7 (ARV7) is one of the best-characterized androgen receptor (AR) variants whose expression in circulating tumor cells (CTCs) ... Read more >>

Cancers (Basel) (Cancers)
[2019, 11(8):]

Cited: 0 times

View full text PDF listing >>



Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.

Ilaria Alborelli, Daniele Generali, Philip Jermann, Maria Rosa Cappelletti, Giuseppina Ferrero, Bruna Scaggiante, Marina Bortul, Fabrizio Zanconati, Stefan Nicolet, Jasmin Haegele, Lukas Bubendorf, Nicola Aceto, Maurizio Scaltriti, Giuseppe Mucci, Luca Quagliata, Giuseppe Novelli,

Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals that could enter into early access prevention programs. Since liquid biopsy is minimally invasive it can be used for longitudinal studies in healthy volunteers to monitor events of progression from normal tissue to pre-cancerous and cancerous condition. Yet, cell-free ... Read more >>

Cell Death Dis (Cell death & disease)
[2019, 10(7):534]

Cited: 0 times

View full text PDF listing >>



PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.

Spasenija Savic, Sabina Berezowska, Serenella Eppenberger-Castori, Gieri Cathomas, Joachim Diebold, Achim Fleischmann, Wolfram Jochum, Paul Komminoth, Thomas McKee, Igor Letovanec, Zerina Jasarevic, Matthias Rössle, Gad Singer, Michael von Gunten, Andreas Zettl, Roland Zweifel, Alex Soltermann, Lukas Bubendorf,

With the approval of pembrolizumab for first- and second-line treatment of PD-L1+ non-small cell lung cancer (NSCLC), PD-L1 testing by immunohistochemistry (IHC) has become a necessity. However, the DAKO autostainer ASL48 for the FDA approved DAKO 22C3 pharmDx assay is not broadly available in Switzerland and other parts of Europe. ... Read more >>

Virchows Arch. (Virchows Archiv : an international journal of pathology)
[2019, 475(1):67-76]

Cited: 0 times

View full text PDF listing >>



Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Deepali Jain, Aruna Nambirajan, Alain Borczuk, Gang Chen, Yuko Minami, Andre L Moreira, Noriko Motoi, Mauro Papotti, Natasha Rekhtman, Prudence A Russell, Spasenija Savic Prince, Yasushi Yatabe, Lukas Bubendorf, ,

With an escalating number of predictive biomarkers emerging in non-small cell lung carcinoma (NSCLC), immunohistochemistry (IHC) is being used as a rapid and cost-effective tool for the screening and detection of many of these markers. In particular, robust IHC assays performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue are widely used ... Read more >>

Cancer Cytopathol (Cancer cytopathology)
[2019, 127(5):325-339]

Cited: 0 times

View full text PDF listing >>



Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pasquale Pisapia, Umberto Malapelle, Gianluca Roma, Sonika Saddar, Qi Zheng, Francesco Pepe, Dario Bruzzese, Elena Vigliar, Claudio Bellevicine, Rajyalakshmi Luthra, Yuri E Nikiforov, Clara Mayo-de-Las-Casas, Miguel Angel Molina-Vila, Rafael Rosell, Michel Bihl, Spasenija Savic, Lukas Bubendorf, Dario de Biase, Giovanni Tallini, David H Hwang, Lynette M Sholl, Sara Vander Borght, Birgit Weynand, Daniel Stieber, Philippe Vielh, Alessandra Rappa, Massimo Barberis, Matteo Fassan, Massimo Rugge, Carlos E De Andrea, Maria D Lozano, Cristiana Lupi, Gabriella Fontanini, Fernando Schmitt, Catherine I Dumur, Bettina Bisig, Massimo Bongiovanni, Sabine Merkelbach-Bruse, Reinhard Büttner, Marina N Nikiforova, Sinchita Roy-Chowdhuri, Giancarlo Troncone, ,

BACKGROUND:Artificial genomic reference standards in a cytocentrifuge/cytospin format with well-annotated genomic data are useful for validating next-generation sequencing (NGS) on routine cytopreparations. Here, reference standards were optimized to be stained by different laboratories before DNA extraction and to contain a lower number of cells (2 × 105 ). This was ... Read more >>

Cancer Cytopathol (Cancer cytopathology)
[2019, 127(5):285-296]

Cited: 1 time

View full text PDF listing >>



Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.

Susan Prendeville, Daniel M Berney, Lukas Bubendorf, Eva Compérat, Lars Egevad, Ondrej Hes, Glen Kristiansen, Jon Oxley, Geert J L H van Leenders, Murali Varma, Theo van der Kwast,

AIMS:Pathological evaluation of lymphadenectomy specimens plays a pivotal role in accurate lymph node (LN) staging. Guidelines standardising the gross handling and reporting of pelvic LN dissection (PLND) in prostate (PCa) and bladder (BCa) cancer are currently lacking. This study aimed to establish current practice patterns of PLND evaluation among pathologists. ... Read more >>

Histopathology (Histopathology)
[2019, 74(6):844-852]

Cited: 0 times

View full text PDF listing >>



Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Alessandra Curioni-Fontecedro, Jean Yannis Perentes, Hans Gelpke, Alexandros Xyrafas, Hasna Bouchaab, Nicolas Mach, Oscar Matzinger, Nina Stojcheva, Martin Frueh, Walter Weder, Richard Cathomas, Piera Gargiulo, Lukas Bubendorf, Miklos Pless, Daniel Betticher, Solange Peters, ,

BACKGROUND:Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CRT) in selected patients (pts) with NSCLC, stage IIIB. METHODS:Resectable stage ... Read more >>

Br. J. Cancer (British Journal of Cancer)
[2019, 120(10):968-974]

Cited: 0 times

View full text PDF listing >>



A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Keith M Kerr, Erik Thunnissen, Urania Dafni, Stephen P Finn, Lukas Bubendorf, Alex Soltermann, Eric Verbeken, Wojciech Biernat, Arne Warth, Antonio Marchetti, Ernst-Jan M Speel, Sarawati Pokharel, Anne Marie Quinn, Kim Monkhorst, Atilio Navarro, Line Bille Madsen, Teodora Radonic, Joan Wilson, Graziano De Luca, Steven G Gray, Richard Cheney, Spasenija Savic, Miguel Martorell, Thomas Muley, Paul Baas, Peter Meldgaard, Fiona Blackhall, Anne-Marie Dingemans, Rafal Dziadziuszko, Johan Vansteenkiste, Walter Weder, Varvara Polydoropoulou, Thomas Geiger, Roswitha Kammler, Solange Peters, Rolf Stahel, ,

INTRODUCTION:The PD-L1 biomarker is an important factor in selecting patients with non-small cell lung cancer for immunotherapy. While several reports suggest that PD-L1 positivity is linked to a poor prognosis, others suggest that PD-L1 positive status portends a good prognosis. METHODS:PD-L1 positivity prevalence, assessed via immunohistochemistry (IHC) on tissue microarrays ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2019, 131:95-103]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.56 s